Share

    


In This Section

Home / Blurb / Discussion Detail

FDA Approves Ponatinib Tablets for Adults with CP CML

Ponatinib (Iclusig, Takeda Oncology) is now now FDA-approved for the treatment of adult patients with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors. 

More information

Posted 1/5/2021